Timing of lifespan influences on brain and cognition

KB Walhovd, M Lövden, AM Fjell - Trends in cognitive sciences, 2023 - cell.com
Modifiable risk and protective factors for boosting brain and cognitive development and
preventing neurodegeneration and cognitive decline are embraced in neuroimaging …

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Alzheimer's disease: exploring the landscape of cognitive decline

R Tenchov, JM Sasso, QA Zhou - ACS Chemical Neuroscience, 2024 - ACS Publications
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by
cognitive decline, memory loss, and impaired daily functioning. The pathology of AD is …

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests

NR Barthélemy, G Salvadó, SE Schindler, Y He… - Nature medicine, 2024 - nature.com
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology

NJ Ashton, WS Brum, G Di Molfetta, AL Benedet… - JAMA …, 2024 - jamanetwork.com
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Alzheimer disease as a clinical-biological construct—an International Working Group recommendation

B Dubois, N Villain, L Schneider, N Fox… - JAMA …, 2024 - jamanetwork.com
Importance Since 2018, a movement has emerged to define Alzheimer disease (AD) as a
purely biological entity based on biomarker findings. The recent revision of the Alzheimer's …

Revised criteria for the diagnosis and staging of Alzheimer's disease

CR Jack Jr, SJ Andrews, TG Beach, T Buracchio… - Nature medicine, 2024 - nature.com
Revised criteria for the diagnosis and staging of Alzheimer’s disease | Nature Medicine Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

Blood biomarkers to detect Alzheimer disease in primary care and secondary care

S Palmqvist, P Tideman, N Mattsson-Carlgren… - JAMA, 2024 - jamanetwork.com
Importance An accurate blood test for Alzheimer disease (AD) could streamline the
diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically …

Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies

N Mattsson-Carlgren, LE Collij, E Stomrud… - JAMA …, 2024 - jamanetwork.com
Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

J Therriault, S Janelidze, AL Benedet, NJ Ashton… - Nature Aging, 2024 - nature.com
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …